JB Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.14M Buy
6,651
+62
+0.9% +$47.5K 0.21% 51
2025
Q4
$5.09M Sell
6,589
-173
-3% -$117K 0.21% 49
2025
Q3
$3.8M Sell
6,762
-142
-2% -$80.3K 0.16% 69
2025
Q2
$3.62M Buy
+6,904
New +$3.85M 0.18% 66
2024
Q4
Sell
-332
Closed -$349K 237
2024
Q3
$349K Buy
332
+3
+0.9% +$3.34K 0.02% 177
2024
Q2
$346K Buy
329
+4
+1% +$3.88K 0.02% 174
2024
Q1
$313K Hold
325
0.02% 178
2023
Q4
$285K Hold
325
0.02% 170
2023
Q3
$267K Hold
325
0.02% 157
2023
Q2
$234K Hold
325
0.02% 157
2023
Q1
$267K Hold
325
0.02% 142
2022
Q4
$234K Buy
+325
New +$240K 0.02% 156

Other funds holding REGN

JB Capital's REGN Position: Q1 2026 in Review

JB Capital increased its Regeneron Pharmaceuticals (REGN) stake by 0.94% in Q1 2026, buying an estimated $47.5K and bringing the position to 6,651 shares worth $5.14M. The position accounts for 0.21% of the portfolio, ranked #51.

JB Capital first reported a position in REGN in Q4 2022 and has held it in 12 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • JB Capital held 6,651 shares of Regeneron Pharmaceuticals worth $5.14M as of Q1 2026.
  • JB Capital bought 62 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $47.5K.
  • Regeneron Pharmaceuticals made up 0.21% of JB Capital's portfolio in Q1 2026, its #51 holding.
  • JB Capital first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on JB Capital's 13F filing for Q1 2026, filed 27 Apr 2026.